

The analgesic efficacy of remifentanyl for labour. Systematic review of the recent literature

Petr Stourac^{a,b}, Martina Kosinova^c, Hana Harazim^c, Martin Huser^d, Petr Janku^d, Simona Littnerova^e, Jiri Jarkovsky^e

Background and Aims. Although epidural analgesia is still regarded as the gold standard for labour analgesia due to its efficacy, in cases of contraindication, systemic remifentanyl is an alternative. Since the first demonstration of the safety of remifentanyl in obstetric analgesia in 1996, this has been repeatedly confirmed for both mother and newborn. The aim of this meta-analysis is to evaluate recently published studies (up to December 2014) on the analgesic efficacy of remifentanyl during labour (as a Visual Analogue Scale (VAS) decrease in the first hour by 2 or more).

Methods. Search of the US National Library of Medicine, National Institutes of Health (www.pubmed.gov), SCOPUS database (www.scopus.com) and Web of Science database (www.webofknowledge.com) using the key words "labour" and "remifentanyl". 44 identified articles were included in the review and 15 published randomised controlled studies were incorporated into the meta-analysis. This was based on the fixed model and described by differences in the VAS between t=0 and t=1 hour after remifentanyl administration using the 95% confidence interval (CI). The analysis was computed using the Comprehensive meta-analysis version 2.2.064.

Results. The combined data from the meta-analysis showed a statistically significant decrease in VAS in the remifentanyl group. From a comparison of the CIs of summary estimates with a cut-off decrease of VAS 2, for the fixed model, there was a statistically significantly greater decrease in VAS than the cut-off. In the systematic review, we describe possible modes of application, dosage and side-effects for mother, fetus/ newborn.

Conclusion. The meta-analysis presented here confirms that remifentanyl for labour analgesia is effective but questions remain which can only be answered by further randomized trials.

Key words: remifentanyl, labour analgesia, patient-controlled analgesia, systemic opioid analgesia, meta-analysis

Received: May 2, 2015; Accepted with revision: September 4, 2015; Available online: October 7, 2015
<http://dx.doi.org/10.5507/bp.2015.043>

^aDepartment of Paediatric Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, Masaryk University, Brno and University Hospital Brno, Czech Republic

^bObstetric Anaesthesia and Analgesia Section of the Czech Society of Anaesthesiology and Intensive Care Medicine, Czech Republic

^cDepartment of Anaesthesiology and Intensive Care Medicine, Faculty of Medicine, Masaryk University, Brno and University Hospital Brno, Czech Republic

^dDepartment of Obstetrics and Gynecology, Faculty of Medicine, Masaryk University, Brno and University Hospital Brno, Czech Republic

^eInstitute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic

Corresponding author: Martina Kosinova, e-mail: mata.kosinova@gmail.com

INTRODUCTION

Most frequent contraindications to epidural analgesia, long considered the "gold" standard for labour analgesia, are refusal of parturient, congenital or acquired coagulopathy and infection¹. The most commonly used opioid in the past was pethidine, despite the well-described side effects of its metabolite, norpethidine, for both mother and newborn²⁻⁷. Another currently used opioid is nalbuphine but this only reduces the pain slightly⁸⁻¹¹.

Remifentanyl is a synthetic 4-anilide-piperidine, side-chain linked by an ester bond, which is responsible for its rapid inactivation by non-specific hydrolysis of plasma and tissue esterases¹². The onset time is reported on average to be 1.3 min and the context-sensitive half-time 3 min, regardless of the duration of the infusion¹³. Remifentanyl is a selective μ -opioid agonist and has the same adverse effects as other opioids. The first demonstration of its use in obstetric analgesia was in 1996 and since then its safety for both mother and newborn has been repeatedly confirmed¹⁴⁻¹⁷.

In European countries, such as Great Britain, Belgium, France and the Scandinavian countries, the administration of remifentanyl for labour is relatively common but not nearly routine^{2,18-20}. The reason for this may be both lack of experience of individual departments with this form of analgesia and the fact that it can be applied almost exclusively with a patient-controlled analgesia pump (PCA) (ref.²¹). Remifentanyl in PCA mode is relatively well-tolerated and this increases the satisfaction of the parturient with pain management^{15,22-24}.

The aim of this meta-analysis was to evaluate the literature on the analgesic efficacy of remifentanyl during labour (measured as a Visual Analogue Scale (VAS) decrease in the first hour by 2 or more). We describe possible modes of application, dosage and side-effects for mother, fetus/ newborn.

Search of the US National Library of Medicine, National Institutes of Health (www.pubmed.gov) using the key words "labour" and "remifentanyl" provided us with 159 links to publications where more than half (82)




Fig. 1. PRISMA flowchart diagram.

Adopted from: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 6(6): e1000097. doi:10.1371/journal.pmed1000097

were published in the last 5 years and only 30 publications were older than 10 years. This confirms that remifentanil is an extremely hot topic in labour anaesthesia.

METHODS

This article followed PRISMA Statement (www.prisma-statement.org) for meta-analysis and reviews.

Searching strategy for review

Search of the US National Library of Medicine, National Institutes of Health (www.pubmed.gov), SCOPUS database (www.scopus.com) and Web of Science database (www.webofknowledge.com) using the key words "labour" and "remifentanil". The last search was performed on December 1, 2014.

Inclusion criteria for meta-analysis

Randomized Controlled Trials (RCTs) meeting the following criteria were included: measured Visual Analogue Scale at time 0 min (t=0) and at 60 min (t=1) after initiation of analgesia; full-text articles available; and presence of detailed clinical data.

Exclusion criteria for meta-analysis

Not randomized controlled study. Missing full article text and missing detailed clinical data or Visual Analogue Scale at times 0 and 60 min.

Statistical analysis

Standard descriptive statistics were applied for VAS, means and standard deviations. The meta-analysis was based on fixed model and described by the difference in the VAS between t=0 and t=1 in the remifentanil group and the corresponding 95% confidence interval. The analysis was computed using the Comprehensive meta-analysis version 2.2.064.

RESULTS

Flowchart

The PRISMA flowchart is shown in Fig. 1. Five national surveys (Table 1), 7 reviews and 2 meta-analyses (Table 2), 17 randomised controlled trials (Table 3), 5 observational studies and 4 initial trials of remifentanil in labour (Table 4) and 2 case reports (Table 5) were included in this review. We also refer to two articles in the

Czech language indexed in SCOPUS, not in pubmed.gov database. One was a Czech national survey of anaesthesiological approaches to obstetric anaesthesia and analgesia. The second was a description of analgesia for labour approaches and experiences in Great Britain^{20,21}. In the final meta-analysis, two RCTs did not meet the inclusion criteria (measured VAS at 60 min) and were excluded from the meta-analysis (Balki et al., Balcioglu et al.) (ref.^{24,25}). The remaining 15 RCTs were analyzed.

Characteristics of included trials

A basic description of included RCTs (mode of administration, dosage, lock out interval, number of conversions to epidural analgesia and compared method of analgesia) is summarized in Table 3.

Primary endpoint

The combined data from the meta-analysis shown in Table 6, revealed a statistically significant decrease in the VAS in the remifentanil group (Table 6, $P < 0.001$). Comparing CIs of summary estimates with a cut-off decrease in VAS of 2, for the fixed model, there was a sta-

References

- Blair et al.²⁷
- Douma et al.³³
- Douma et al.⁴³
- El-Kerdawy et al.⁴²
- Evron et al.²⁸
- Evron et al.³⁵
- Ismail et al.⁴⁴
- Ng et al.⁴⁰
- Stocki et al.¹⁷
- Štourač et al.¹⁵
- Thurlow et al.⁴⁶
- Tveit et al.³⁴
- Volikas et al.²⁶
- Volmanen et al.³⁷
- Volmanen et al.⁴¹

Fixed model

Difference in means and 95% CI




Fig. 2. Meta-analysis for VAS change in first 60 minutes of remifentanil analgesia.

VAS - Visual Analogue Scale, 95% CI - 95% Confidence Interval

Table 1. National surveys on labour analgesia including remifentanil.

Reference	Country	Questioned units / responded / response rate [%]	Goal or result
Saravanakumar et al. ²	UK	243 / 159 / 65	Availability of methods for pain relief other than regional block
Schnabel et al. ³	Germany	930 / 343 / 37	Current use of intravenous opioids with a focus on remifentanil as PCA in obstetrics. Remifentanil in PCA in 68 %
Štourač et al. ²¹	Czech Republic	97 / 49 / 51	Czech national survey on obstetric analgesia and anaesthesia
Hanouz et al. ¹⁸	France	240 / 103 / 43	In 52% of French hospitals, there was a written protocol for an alternative to epidural analgesia for analgesia during labour
Lavand'homme et al. ¹⁹	Belgium	53 / 36 / 68	47% of centres used PCA if epidural analgesia was contraindicated. In 77% of cases remifentanil was first choice

UK - United Kingdom, CR - Czech Republic, PCA - Patient controlled analgesia

Table 2. Review articles on remifentanil or other alternative labour analgesia and a meta-analysis of randomised controlled trials that compared remifentanil PCA.

Reference	Topic of review article
Reynolds ⁷	Comparison of IV opioid analgesia, Entonox, neuraxial analgesia on neonatal outcome
Egan ¹³	Pharmacokinetics and pharmacodynamics of remifentanil
Leong et al. ³⁸	A comparison between remifentanil and meperidine for labor analgesia
Hill et al. ⁵⁵	The use of remifentanil in obstetric anaesthesia and analgesia
Hinova et al. ⁵⁶	Efficacy of remifentanil as a labor analgesic
Volmanen et al. ⁵⁷	Comparison of paracervical block, pudendal block, IV remifentanil and nitrous oxide
Kranke et al. ⁵⁸	Safety of remifentanil in labour analgesia

Reference of meta-analysis	N	n remifentanil / other	Compared methods
Liu et al. ¹⁴	5 RCT	443 / 443	remifentanil PCA, EA
Schnabel et al. ³⁹	12 RCT	269 / 324	remifentanil PCA, pethidine, nitrous oxide, fentanyl, EA

IV - intravenous N - number of trials, n - number of patients, RCT - randomised controlled trial, PCA - Patient controlled analgesia, EA - epidural analgesia

Table 3. Remifentanil RCTs that evaluated the efficacy for labour analgesia.

Reference	Remifentanil			Comparator
	Bolus [$\mu\text{g}/\text{kg}$] or infusion [$\mu\text{g}/\text{kg}/\text{min}$]	Lock out [min]	Conversion to EA [N]	
Douma et al. ³³	B: 0.5	2	7	Pethidine IV Fentanyl IV
Evron et al. ³⁵	B: 0.27 - 0.93	3	5	Pethidine IV
Ng et al. ⁴⁰	B: 0.37 - 0.44	3.75-4.5	0	Pethidine IV
Blair et al. ²⁷	B: 0.5	2	2	Pethidine IV
Volikas et al. ²⁶	B: 0.5	2	1	Pethidine IV
Štourač et al. ¹⁵	B: 0.24	3	0	EA:Bupivacain + sufentanil
Tveit et al. ³⁴	B: 0.15 + increase in steps of 0.15 until relief	2	2	EA:Ropivacain + fentanyl
Volmanen et al. ⁴¹	B: 0.3 - 0.7	1	NR	EA:Levobupivacain + fentanyl
El-Kerdawy et al. ⁴²	B: 0.5 loading bolus, 0.25; I: 0.05; (max 3 mg/4hr)	5	NR	EA:Bupivacain + fentanyl
Douma et al. ⁴³	B: 0.5	2	1	EA:Bupivacain + sufentanil
Ismail et al. ⁴⁴	B: 0.1 - 0.9	1	0	EA:Levobupivacain + fentanyl CSE:Levobupivacain + fentanyl
Stocki et al. ¹⁷	B: 20 - 60 μg	1-2	3	EA:Bupivacain + fentanyl
Evron et al. ²⁸	B:20 μg ; I:0.025	3	NR	EA:Ropivacain EA:Ropivacain + IV remifentanil EA:Ropivacain + IV acetaminophen
Volmanen et al. ³⁷	B: 0.4	1	NR	50% N ₂ O
Thurlow et al. ⁴⁶	B: 20 μg	3	2	Pethidine IM
Balcioglu et al. ^{25*}	I _r : 0.1 I _r : 0.15	NA	NA	-
Balki et al. ²⁴	Basal I: 0.025, Basal B: 0.25	2	NA	group A: I increase 0.025-0.1 group B: B increase 0.25-1

B - bolus; I - infusion; N - number, NR - Not Reported; NA - not available, IV - intravenous, RCT - Randomized Controlled trial, EA - epidural analgesia; CSE - Combined spinal-epidural analgesia

* 2 groups with different background infusion: r (N = 30), R (N = 30)

f - numbers estimated from figure

tistically significantly greater decrease in VAS than the cut-off (Fig. 2).

DISCUSSION AND REVIEW OF THE LITERATURE

To the best of our knowledge, this is the first meta-analysis of RCTs on the efficacy of remifentanil during labour, regardless of study design, mode of application and dosage of remifentanil during labour.

The strength of the meta-analysis is inclusion of all RCTs published until the end of 2014 with the exception of RCTs which failed to meet the criteria for analysis.

The key information is that 12 RCTs showed a statistically significant decrease in VAS in the first hour. Two showed nonsignificant change in VAS in the first hour (Volikas et al., Blair et al.) and only one (Evron et al.) reported a statistically significant increase in VAS (ref.²⁶⁻²⁸). The primary outcome of Evron's study was the effect of remifentanil on body temperature during labour²⁸. The three studies above confirmed the superiority of remifentanil in terms of analgesic efficacy compared to remifentanil with pethidine during labour.

Safety and efficacy of remifentanil in labour

As published, remifentanil relieves pain in labour during the first stage^{15,29-31}. Typically described is initial decrease in the intensity of labour pain during the first hour following remifentanil and then a return of pain intensity to initial values, even using a different application method and dose^{14,15,29,31,32}. Despite this course, surprisingly few subsequent applications of epidural analgesia are described for inadequate pain relief using remifentanil (0-10%) which is hard to explain from the published data^{28,29,33-35}. During the second stage of labour, pain intensity remains high but the reduction in pain is perceived by the patient as adequate (Table 4) (ref.^{30,34}).

Comparison of the efficacy and safety of remifentanil with other types of analgesia in labour

There are no published RCT studies directly comparing the analgesic efficacy of remifentanil for labour with placebo.

Nitrous oxide

Nitrous oxide in the form of Entonox® (50% N₂O a 50% O₂, LINDE GAS) celebrates a return to the delivery room. Currently available is one Iranian study on the ef-

Table 4. Observational studies of remifentanil intravenous analgesia and initial studies of remifentanil in labour.

Observational studies					
References	n	Way of R administration	Dose	Lock out interval	Observed parameter
D'Onofrio et al. ²²	205	Continuous IV	0.02-0.15 µg/kg/min	-	Maternal pain, maternal and fetal variables, side-effects, satisfaction
Buehner et al. ²³	244	PCA	0.5-1.0 µg/kg	1-2 min	Satisfaction, maternal side-effects, Apgar score
Kan et al. ¹⁶	19	Continuous IV	0.1 µg/kg/min	-	Concentrations of remifentanil, its metabolite, and blood gases in MA, UA and UV blood samples
Volikas et al. ²⁹	50	PCA	0.5 µg/kg	2 min	VAS, nausea, itching, fetal heart rate, UA gases, 1 and 5 min Apgar scores, neurological evaluation of the neonate, remifentanil concentration in MV, UA, UV blood samples
Marwah et al. ³²	98	PCA	B: 0.25 µg/kg, I: 0.025-0.05 µg/kg/min	2 min	Maternal pain scores, sedation scores, adverse effects, neonatal outcomes

Initial studies			
References	n	Type of study	Goal
Blair et al. ³⁰	21	Feasibility study	Remifentanil PCA (B 0.25-0.5 µg/kg)
Volmanen et al. ³¹	17	Dose finding study	The median effective PCA: B: 0.4 µg/kg, I: 0.066 µg/kg/min
Huang et al. ⁴⁵	0	Experimental analysis	Prediction of the occurrence of labor contractions
Babenco et al. ⁴⁸	8	Observational study	Healthy volunteers, respiratory depression

n - number of patients; IV - intravenous, PCA - Patient controlled analgesia, NA - Not Available, R - remifentanil, MV - maternal vena, MA - maternal arteria, UA - umbilical arteria, UV - umbilical vena, VAS - Visual Analogue Scale, B = bolus, I = basal infusion

efficacy and safety of nitrous oxide during labour. It describes a surprisingly high incidence of side-effects³⁶. The analgesic efficacy of remifentanil compared to 50% N₂O was five times higher than that published by Volmanen et al.³⁷ Mothers themselves preferred the administration of remifentanil. The disadvantage of remifentanil was a higher level of sedation but no serious episodes of hypoxia (SpO₂ <90%) occurred. The authors found no differences in maternal hemodynamics or early postnatal adaptation of newborns.

Pethidine

A systematic review comparing the use of remifentanil and pethidine in the management of labour pain, clearly documents the greater efficacy of remifentanil³⁸. In this study, remifentanil was more effective on the VAS scale 25 millimeters, than pethidine within the first hour after application. The maternal satisfaction with remifentanil was higher and necessity for subsequent application of epidural analgesia for inadequate pain relief was lower³⁹. Due to the large heterogeneity of dosing schedules of both drugs, it is difficult to draw clear conclusions about the side-effects. There were no differences in the incidence of decreased saturation below 95% or in maternal sedation. Some studies found no difference in cardiocograph interpretation^{33,40}. On the other hand, one study showed

a lower incidence of non-physiological cardiocograph when remifentanil was administered³⁵. All studies confirmed better postpartum neonatal outcome after remifentanil than pethidine (Table 3) (ref.^{26,27}).

Epidural analgesia

The most interesting and most useful in practice, is comparison of remifentanil with epidural analgesia. Although epidural analgesia is provided in less than 15% of labours in some countries, it is the major analgesic method used by anaesthesiologists in obstetrics in the Czech Republic²¹. Currently, few probably doubt that remifentanil administered in the PCA is a less effective analgesic than epidural analgesia^{14,15}. Despite these findings, most studies found no difference in maternal satisfaction with applied method of analgesia^{15,18,34,41-44}. This would suggest that remifentanil provides a weaker but highly acceptable analgesia for the parturient. The explanation for this may be opioid-induced euphoria⁴¹. In contrast, remifentanil is associated with a higher risk of nausea and vomiting, decreased oxygen saturation under 95% and dose dependent level of sedation^{34,39,41}. There was no difference in either cardiocograph interpretation or neonatal outcome between epidural analgesia and remifentanil^{15,28,34,41,43,44}. No effect on higher incidence of instrumental deliveries, Caesarean Sections or length of

Table 5. Case reports of patients using patient controlled analgesia.

Reference	Case description
Bonner et al. ⁵³	Respiratory arrest in patient using remifentanyl in PCA
Marr et al. ⁵⁴	Cardiorespiratory arrest during induced labour while using a remifentanyl PCA in patient diagnosed with an intrauterine death at 31 weeks' gestation

PCA - Patient controlled analgesia

Table 6. Meta-analysis of study results comparing VAS between t=0 and t=1 hour for remifentanyl.

Study	Difference in VAS between t=0 and t=1 for Remifentanyl (95% CI)	P
Blair et al. ²⁷	0.300 (-1.324; 1.924)	0.718
Douma et al. ³³	-3.240 (-4.024; -2.456)	<0.001
Douma et al. ⁴³	-3.800 (-5.387; -2.213)	<0.001
El-Kerdawy et al. ⁴²	-4.900 (-5.898; -3.902)	<0.001
Evron et al. ²⁸	1.900 (1.399; 2.401)	<0.001
Evron et al. ³⁵	-5.040 (-5.931; -4.149)	<0.001
Ismail et al. ⁴⁴	-3.210 (-3.362; -3.058)	<0.001
Ng et al. ⁴⁰	-3.220 (-4.491; -1.949)	<0.001
Stocki et al. ¹⁷	-4.100 (-5.072; -3.128)	<0.001
Štourač et al. ¹⁵	-2.400 (-2.850; -1.950)	<0.001
Thirlow et al. ⁴⁶	-2.300 (-3.850; -0.750)	0.006
Tveit et al. ³⁴	-4.400 (-5.437; -3.363)	<0.001
Volikas et al. ²⁶	-1.900 (-4.487; 0.687)	0.162
Volmanen et al. ³⁷	-1.900 (-3.072; -0.728)	0.003
Volmanen et al. ⁴¹	-1.000 (-1.854; -0.146)	0.025
Summary - fixed model	-2.826 (-2.953; -2.699)	<0.001

VAS - Visual Analogue Scale, 95% CI - 95% Confidence Interval

delivery stages 1 and 2 were established either (Table 3) (ref.^{15,17}).

Dosing and mode of remifentanyl administration during labour

Remifentanyl is administered intravenously using infusion pump with PCA mode preferably without any further IV fluid administered into identical intravenous cannula. Currently available are various products containing remifentanyl: Ultiva (GSK, Great Britain), Remifentanyl B.Braun (B.Braun, Germany), Remifentanyl Kabi (Fresenius Kabi, Germany) and others. The package contains 1 or 2 mg of active substance in the vial. Remifentanyl usually needs to be diluted with saline to achieve a concentration of 20 or 50 µg/mL (ref.^{15,20}). The setup for PCA mode in published studies is variable and optimal dosing schedules have not yet been described (Table 3) (ref.¹⁴).

Bolus versus continuous application

The first dose determining studies identified the effective dose as 0.25 - 0.5 µg/kg for obstetric analgesia (Table 4) (ref.^{30,31}). Subsequent studies have worked with different dosages ranging from 0.1-0.9 µg/kg in case of conversion of the dose per body weight or fixed bolus 20-50 µg (ref.¹⁵). Lock out interval (interval in which the pump does not respond to parturient requirements) varied

between 1 and 3 min with the exception of two studies, where the lock out interval was 4.5 min and 5 min^{40,42}. A maximum average single dose of 0.7 µg/kg was published by Tveit. This author also warned about exceeding this dose because of higher risk of desaturation and maternal sedation³⁴. On the other hand, D'Onofrio did not apply bolus doses, only continual infusion of remifentanyl in a range of 0.025 to 0.15 µg/kg/min (ref.²²).

Fixed versus variable dose of remifentanyl

Labour pain is intermittent, dynamic and specific with increasing frequency and intensity during labour progression. For this reason, proper timing, dosing and length of lock out interval are important for analgesic efficacy. The beginning of subsequent contractions is also unpredictable due to interindividual variability even with the involvement of highly advanced machine learning methods⁴⁵. This fact could explain the considerable variation in dose and cumulative dose of remifentanyl during labour in most published studies¹². A fixed dose without the option of reacting to actual need can therefore lead to either underdosing with insufficient pain relief or overdosing associated with side-effects^{27,46}. Some studies refute this concern^{33,40,43}. The question of preferences of fixed dose or variable dose therefore remains open.

Basal infusion

Another controversial issue in the administration of remifentanyl at delivery, is application of basal infusion in the period between bolus applications. In studies where basal infusion was used, the dose varied between 0.025 and 0.15 µg/kg/min. Blair et al. reported that basal infusion does not lead to greater analgesic efficacy but only to higher incidence of respiratory depression and maternal sedation³⁰. On the other hand, Balki explained the low rate of need for loading epidural analgesia due to inefficacy of remifentanyl with administering the variable basal infusion (0.025-0.1 µg/kg/min with bolus dose 0.25 µg/kg) (ref.²⁴).

Comparison of different modes of administration of remifentanyl

Few studies are available that directly compare different modes of administering remifentanyl at delivery. Balcioğlu et al. compared two PCA modes with different basal infusion of remifentanyl. A basal infusion of 0.15 µg/kg/min was found to be the more effective analgesic dose than 0.1 µg/kg/min without the described difference in adverse effects for both mother and newborn²⁵. Balki et al. compared two modes of remifentanyl administration, one with variable bolus dose and fixed basal infusion and in contrast, the second with variable basal infusion and fixed bolus dose²⁴. Analgesic efficacy, maternal satisfaction and cumulative intake of remifentanyl were comparable. Side-effects, especially drowsiness, were higher in the group with the variable bolus. Apropos the pharmacokinetics of remifentanyl and the character of labour pain, initiation of remifentanyl administration with the beginning of contraction may not lead to the greatest effect at the time of the most intensive labour pain^{47,48}. For this reason, Volmanen et al. investigated remifentanyl administration either at the beginning of contraction or between two contractions⁴⁹. They reported no differences in analgesic efficacy or incidence of side-effects between groups. However, more detailed analysis showed that in a group of patients with long and regular contractions, a bolus dose between contractions can have greater analgesic effects.

Adverse effects of remifentanyl in labour

Remifentanyl, as with other opioids, can potentially cause serious adverse effects. Various depth of maternal sedation is common^{15,29,31,37,41}. The incidence of sedation in some studies is almost 100% (ref.^{24,31,34}). Other frequent negative effects of opioids, including remifentanyl are nausea and vomiting. Some publications do not describe a higher incidence in the case of remifentanyl^{14,15,17,24,31,34}. The occurrence of dizziness may disable further use of remifentanyl due to risk of falling during verticalization^{40,41}. An incidence of maternal desaturation under 95% is published in 24 - 74% of cases^{17,30,31,33,41,46}. This is no higher than pethidine³⁸. Interestingly, desaturation occurs in 40% of parturients inhaling Entonox[®] and in 46% of parturients without any analgesia^{50,51}. Episodes of desaturation associated with remifentanyl are usually short and rapidly respond to maternal stimulation or oxygen

application. The most severe cases may result in apnea and several have been reported^{17,52-54}. The one requiring artificial ventilation reported by Bonner and McClymont was related to a combination of other factors such as dehydration, exhaustion and vertical position of the parturient⁵³. Recently, a case report of cardiac arrest following respiratory arrest after remifentanyl was published⁵⁴. Long term opioids (codein, diamorphine) preceded this event in the reported case. Although the full recovery of parturient occurred after resuscitation, fatal intrauterine death took place during the complication. This incident led to recommendations for careful maternal monitoring after remifentanyl, including continuous monitoring of respiratory rate and oxygen saturation and one midwife per parturient. There is also the need for rapid availability of anaesthesiologist to deal with any complications^{24,27,55-57}. Implementation all of these conditions may not be easy to achieve in an exposed delivery room in a large perinatal center. After the initial labelling of remifentanyl as "The poor man's epidural", it seems that for its safe use we must require at least the same conditions as for epidural analgesia⁵⁸.

Adverse effects of remifentanyl on the fetus and neonate

Although remifentanyl rapidly crosses the placenta into the fetal circulation (88% concentration in the fetus), it is rapidly metabolized and redistributed in newborn (the concentration ratio uterine vein to uterine artery is 0.29) (ref.¹⁶). The risk for neonate appears to be minimal. Further studies confirm this and to date no adverse neonatal outcome (Apgar score, uterine blood gases or need to give naloxone) has been proven^{14,15,17,22,23,30,43}. Neither has any typical pathological cardiocograph curve associated with remifentanyl in labour been found. One caveat is the small number of cases of impaired neonatal outcome that may cause a feeling of false security around remifentanyl use for newborns²⁹. For this reason, the necessary equipment of the delivery room for eventual resuscitation of newborns must include naloxone. Based on the current published data, we cannot answer questions concerning the relationship of possible impairment in neonatal outcome and dosage to the method of application of remifentanyl.

However, we recommend the following dose regimen without background infusion, low initial dose with the option of bolus adjustment or/and lock out intervals based on clinical status of the parturient and termination of boluses at the start of the second stage of labour, to minimize maternal hypoventilation and adverse postnatal effects on the newborn⁵⁹.

CONCLUSION

This meta-analysis confirms the efficacy of remifentanyl for labour. The systematic review describes possible modes of application, dosage and side-effects for mother, fetus/ newborn. However, questions remain which can only be answered by further randomized trials.

Acknowledgement: Many thanks to Alena Stouracova for review of the article and Alexander Oulton for proof reading.

Author contributions: PS, MK, HH, MH, PJ, SL, JJ: designed the meta-analysis and review, literature search, statistical analysis, manuscript writing, final approval, SL, JJ: statistical analysis, graphs.

Conflict of interest statement: The authors state that there are no conflicts of interest regarding the publication of this article.

REFERENCES

- Bonnet A, Chevalier Y, Wallon G, Huissoud C, Aubrun F. Peripartum period and hemophilia carriers. *Ann Fr Anesth Reanim* 2013;32(11):807-10.
- Saravanakumar K, Garstang JS, Hasan K. Intravenous patient-controlled analgesia for labour: a survey of UK practice. *Int J Obstet Anesth* 2007;16(3):221-5.
- Schnabel A, Hahn N, Muellenbach R, Frambach T, Hoenig A, Roewer N, Kranke P. Obstetric analgesia in German clinics. remifentanyl as alternative to regional analgesia. *Anaesthesist* 2011;60(11):995-1001.
- Pařízek A, Bláha J, Nosková P. [Obstetric analgesia and anesthesia in the Czech Republic in 2012. 20th anniversary of postgraduate education program]. *Ceska Gynekologie* 2012;77(4):346-9. [In Czech].
- Belfrage P, Boréus LO, Hartvig P, Irestedt L, Raabe N. Neonatal depression after obstetrical analgesia with pethidine. The role of the injection-delivery time interval and of the plasma concentrations of pethidine and norpethidine. *Acta Obstet Gynecol Scand* 1981;60(1):43-9.
- Kuhnert BR, Philipson EH, Kuhnert PM, Syracuse CD. Disposition of meperidine and normeperidine following multiple doses during labor. II. Fetus and neonate. *Am J Obstet Gynecol* 1985;151(3):410-5.
- Reynolds F. The effects of maternal labour analgesia on the fetus. *Best Pract Res Clin Obstet Gynaecol* 2010;24(3):289-302.
- Vavřínková B, Binder T, Horák J. [Nalbuphine in obstetrical analgesia.] *Ceska Gynekologie* 2010;75(6):563-8. [In Czech]
- Soontrapa S, Sombornporn W, Komwilaisak R, Sookpanya S. Effectiveness of intravenous meperidine for pain relief in the first stage of labour. *J Med Assoc Thai* 2002;85(11):1169-75.
- Olofsson C, Ekblom A, Ekman-Ordeberg G, Hjelm A, Irestedt L. Lack of analgesic effect of systemically administered morphine or pethidine on labour pain. *Br J Obstet Gynaecol* 1996;103(10):968-72.
- Tsui MH, Ngan Kee WD, Ng FF, Lau TK. A double blinded randomised placebo-controlled study of intramuscular pethidine for pain relief in the first stage of labour. *Br J Obstet Gynaecol* 2004;111(7):648-55.
- Glass PS, Hardman D, Kamiyama Y, Quill TJ, Marton G, Donn KH, Grosse CM, Hermann D. Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanyl (G187084B). *Anesth Analg* 1993;77(5):1031-40.
- Egan TD. Pharmacokinetics and pharmacodynamics of remifentanyl: an update in the year 2000. *Curr Opin Anaesthesiol* 2000;13(4):449-55.
- Liu ZQ, Chen XB, Li HB, Qiu MT, Duan T. A comparison of remifentanyl parturient-controlled intravenous analgesia with epidural analgesia: a meta-analysis of randomized controlled trials. *Anesth Analg* 2014; 118(3):598-603.
- Stourac P, Suchomelova H, Stodulkova M, Huser M, Krikava I, Janku P, Haklova O, Hakl L, Stoudek R, Gal R, Sevcik P. Comparison of Parturient-Controlled Remifentanyl with Epidural Bupivacain and Sufentanyl for Labour Analgesia: Randomised Controlled Trial. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2014;158(2):227-32.
- Kan RE, Hughes SC, Rosen MA, Kessin C, Preston PG, Lobo EP. Intravenous remifentanyl: placental transfer, maternal and neonatal effects. *Anesthesiology* 1998;88(6):1467-74.
- Stocki D, Matot I, Einav S, Eventov-Friedman S, Ginosar Y, Weiniger CF. A Randomized Controlled Trial of the Efficacy and Respiratory Effects of Patient-Controlled Intravenous Remifentanyl Analgesia and Patient-Controlled Epidural Analgesia in Laboring Women. *Anesth Analg* 2014;118(3):589-97.
- Hanouz JL, Simonet T, Marliot C, Mayaud A, Girard A, Rakotnirina N, Fellahi JL, Gérard JL. French national survey on remifentanyl utilisation for obstetrical peridural analgesia. *Ann Fr Anesth Reanim* 2012;31(9):682-6. [In French]
- Lavand'homme P, Roelants F. Patient-controlled intravenous analgesia as an alternative to epidural analgesia during labor: questioning the use of the shortacting opioid remifentanyl. Survey in the French part of Belgium (Wallonia and Brussels). *Acta Anaesthesiol Belg* 2009;60(2):75-82.
- Matloch Z, Matlochová S. [Obstetric analgesia from the perspective of the anaesthesiologist - Experience from the UK]. *Anest Intenziv Med* 2013;24(2):102-6. [In Czech].
- Štourač P. [Obstetric Anaesthesia and Analgesia Month Attributes –report about anaesthesiology experience in Czech obstetric departments]. *Anest Intenziv Med* 2013;24 (2):81-2. [In Czech].
- D'Onofrio P, Novelli AM, Mecacci F, Scarselli G. The efficacy and safety of continuous intravenous administration of remifentanyl for birth pain relief: an open study of 205 parturients. *Anesth Analg* 2009;109(6):1922-4.
- Buehner U, Broadbent JR, Chesterfield B. Remifentanyl patient-controlled analgesia for labour: a complete audit cycle. *Anaesth Intensive Care* 2011;39(4):666-70.
- Balki M, Kasodekar S, Dhumne S, Bernstein P, Carvalho JC. Remifentanyl patient-controlled analgesia for labour: optimizing drug delivery regimens. *Can J Anaesth* 2007;54(8):626-33.
- Balcioglu O, Akin S, Demir S, Aribogana A. Patient-controlled intravenous analgesia with remifentanyl in nulliparous subjects in labor. *Expert Opin Pharmacother* 2007;8(18):3089-96.
- Volikas I, Male D. A comparison of pethidine and remifentanyl patient-controlled analgesia in labour. *Int J Obstet Anesth* 2001;10(2):86-90.
- Blair JM, Dobson GT, Hill DA, McCracken GR, Fee JP. Patient controlled analgesia for labour: a comparison of remifentanyl with pethidine. *Anaesthesia* 2005;60(1):22-7.
- Evron S, Ezri T, Protianov M, Muzikant G, Sadan O, Herman A, Szmuk P. The effects of remifentanyl or acetaminophen with epidural ropivacaine on body temperature during labor. *J Anesth* 2008;22(2):105-11.
- Volikas I, Butwick A, Wilkinson C, Fleming A, Nicholson G. Maternal and neonatal side-effects of remifentanyl patient controlled analgesia in labour. *Br J Anaesth* 2005;95(4):504-9.
- Blair JM, Hill DA, Fee JP. Patient-controlled analgesia for labour using remifentanyl: a feasibility study. *Br J Anaesth* 2001;87(3):415-20.
- Volmanen P, Akural EI, Raudaskoski T, Alahuhta S. Remifentanyl in obstetric analgesia: a dose-finding study. *Anesth Analg* 2002;94(4):913-7.
- Marwah R, Hassan S, Carvalho JC, Balki M. Remifentanyl versus fentanyl for intravenous patientcontrolled labour analgesia: an observational study. *Can J Anaesth* 2012;59(3):246-54.
- Douma MR, Verwey RA, Kam-Endtz CE, van der Linden PD, Stienstra R. Obstetric analgesia: a comparison of patient-controlled meperidine, remifentanyl, and fentanyl in labour. *Br J Anaesth* 2010;104(2):209-15.
- Tveit TO, Seiler S, Halvorsen A, Rosland JH. Labour analgesia: a randomised, controlled trial comparing intravenous remifentanyl and epidural analgesia with ropivacaine and fentanyl. *Eur J Anaesthesiol* 2012;29(3):129-36.
- Evron S, Glezerman M, Sadan O, Boaz M, Ezri T. Remifentanyl: a novel systemic analgesic for labor pain. *Anesth Analg* 2005;100(1):233-8.
- Pasha H, Basirat Z, Hajahmadi M, Bakhtiari A, Faramarzi M, Salmalian H. Maternal expectations and experiences of labor analgesia with nitrous oxide. *Iran Red Crescent Med J* 2012;14(12):792-7.
- Volmanen P, Akural E, Raudaskoski T, Ohtonen P, Alahuhta S. Comparison of remifentanyl and nitrous oxide in labour analgesia. *Acta Anaesthesiol Scand* 2005;49(4):453-8.
- Leong WL, Sng BL, Sia AT. A comparison between remifentanyl and meperidine for labor analgesia: a systematic review. *Anesth Analg* 2011;113(4):818-25.
- Schnabel A, Hahn N, Broscheit J, Muellenbach RM, Rieger L, Roewer N, Kranke P. Remifentanyl for labour analgesia: a meta-analysis of randomised controlled trials. *Eur J Anaesthesiol* 2012;29(4):177-85.
- Ng TK, Cheng BC, Chan WS, Lam KK, Chan MT. A double-blind randomised comparison of intravenous patientcontrolled remifent-

- anil with intramuscular pethidine for labour analgesia. *Anaesthesia* 2011;66(9):796-801.
41. Volmanen P, Sarvela J, Akural EI, Raudaskoski T, Korttila K, Alahuhta S. Intravenous remifentanyl vs. epidural levobupivacaine with fentanyl for pain relief in early labour: a randomised, controlled, double-blind study. *Acta Anaesthesiol Scand* 2008;52(2):249-55.
 42. El-Kerdawy H, Farouk A. Labor analgesia in preeclampsia: remifentanyl patient controlled intravenous analgesia versus epidural analgesia. *Middle East J Anesthesiol* 2010;20(4):539-45.
 43. Douma MR, Middeldorp JM, Verwey RA, Dahan A, Stienstra R. A randomised comparison of intravenous remifentanyl patient-controlled analgesia with epidural ropivacaine/sufentanyl during labour. *Int J Obstet Anesth* 2011;20(2):118-23.
 44. Ismail MT, Hassanin MZ. Neuraxial analgesia versus intravenous remifentanyl for pain relief in early labor in nulliparous women. *Arch Gynecol Obstet* 2012;286(6):1375-81.
 45. Huang Z, Shyu ML, Tien J, Vigoda M, Birnbach D. Knowledge-Assisted Sequential Pattern Analysis with Heuristic Parameter Tuning for Labor Contraction Prediction. *IEEE J Biomed Health Inform* 2014;18(2):492-9.
 46. Thurlow JA, Laxton CH, Dick A, Waterhouse P, Sherman L, Goodman NW. Remifentanyl by patient-controlled analgesia compared with intramuscular meperidine for pain relief in labour. *Br J Anaesth* 2002;88(3):374-8.
 47. Ngan Kee WD, Khaw KS, Ma KC, Wong AS, Lee BB, Ng FF. Maternal and neonatal effects of remifentanyl at induction of general anesthesia for cesarean delivery: a randomized, double-blind, controlled trial. *Anesthesiology* 2006;104(1):14-20.
 48. Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect of a remifentanyl bolus on ventilatory control. *Anesthesiology* 2000;92(2):393-8.
 49. Volmanen PV, Akural EI, Raudaskoski T, Ranta P, Tekay A, Ohtonen P, Alahuhta S. Timing of intravenous patient-controlled remifentanyl bolus during early labour. *Acta Anaesthesiol Scand* 2011;55(4):486-94.
 50. Arfeen Z, Armstrong PJ, Whitfield A. The effects of Entonox and epidural analgesia on arterial oxygen saturation of women in labour. *Anaesthesia* 1994;49(1):32-4.
 51. Griffin RP, Reynolds F. Maternal hypoxaemia during labour and delivery: the influence of analgesia and effect on neonatal outcome. *Anaesthesia* 1995;50(2):151-6.
 52. Waring J, Mahboobi SK, Tyagaraj K, Eddi D. Use of remifentanyl for labor analgesia: the good and the bad. *Anesth Analg* 2007;104(6):1616-7.
 53. Bonner JC, McClymont W. Respiratory arrest in an obstetric patient using remifentanyl patient-controlled analgesia. *Anaesthesia* 2012;67(5):538-40.
 54. Marr R, Hyams J, Bythell V. Cardiac arrest in an obstetric patient using remifentanyl patient-controlled analgesia. *Anaesthesia* 2013;68(3):283-7.
 55. Hill D. Remifentanyl in obstetrics. *Curr Opin Anaesthesiol* 2008;21(3):270-4.
 56. Hinova A, Fernando R. Systemic remifentanyl for labor analgesia. *Anesth Analg* 2009;109(6):1925-9.
 57. Volmanen P, Palomaki O, Ahonen J. Alternatives to neuraxial analgesia for labor. *Curr Opin Anaesthesiol* 2011;24(3):235-41.
 58. Kranke P, Girard T, Lavand'homme P, Melber A, Jokinen J, Muellenbach RM, Wirbelauer J, Hönig A. Must we press on until a young mother dies? Remifentanyl patient controlled analgesia in labour may not be suited as a "poor man's epidural". *BMC Pregnancy Childbirth* 2013;13:139.
 59. Stourac P, Brachaczkova Z, Holecckova P, Nedomova L. Obstetric Analgesia. Educational portal AKUTNE.CZ [serial on the internet, ISSN 1803-179X]. 2015 Jun [cited 2015 Jul 16]. Available from: <http://www.akutne.cz/index-en.php?pg=education--interactive-algorithms&tid=209>